N@N

Gregory Renza Maintained (ACAD) at Buy with Increased Target to $33 on, Jul 14th, 2023

Gregory Renza of RBC Capital, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $28 to $33 on, Jul 14th, 2023.

Gregory has made no other calls on ACAD in the last 4 months.

There are 6 other peers that have a rating on ACAD. Out of the 6 peers that are also analyzing ACAD, 3 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Uy Ear of "Mizuho" Reiterated at Hold and Held Target at $20 on, Wednesday, June 14th, 2023
• Tazeen Ahmad of "B of A Securities" Maintained at Hold with Increased Target to $26 on, Monday, May 22nd, 2023
• Julio Romero of "JP Morgan" Maintained at Hold with Increased Target to $21 on, Monday, March 20th, 2023

These are the ratings of the 3 analyists that currently disagree with Gregory

---

• Sarah James of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $33 on, Tuesday, May 9th, 2023
• Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $33 on, Tuesday, March 14th, 2023
• Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $26 on, Tuesday, March 14th, 2023

Contributing Sources

---